RevBio Secures Groundbreaking Patent for Innovative Regenerative Bone Adhesive Technology

The 10^th Patent for TETRANITE® Expands RevBio’s Protection for Innovative Bio Adhesive Technology

LOWELL, Mass., January 30, 2025–(BUSINESS WIRE)–The U.S. Patent and Trademark Office has awarded patent 12,178,937, titled “Compositions and Methods for Adhesion to Surfaces.” This marks the 10^th patent related to TETRANITE bone adhesive technology. It now includes injectable bone adhesives containing alpha tricalcium phosphate, further enhancing RevBio’s technology portfolio. This patent complements another U.S. patent, 11,638,777, which covers methods for repairing fractured bones using this adhesive.

“This patent strengthens RevBio’s intellectual property in the field of mineral-organic bone adhesives,” said George Kay, DMD, Chief Scientific Officer. “Our TETRANITE biomaterial combines strong handling, high strength, and biocompatibility with unique adhesive properties.”

RevBio, formerly LaunchPad Medical, holds an exclusive patent license from Stryker Corporation covering various patent families related to its bone adhesive technology. This protection lasts until 2033, allowing RevBio ample time to develop and market its TETRANITE products.

Since 2016, RevBio has filed fourteen Patent Cooperation Treaty (PCT) applications to safeguard its growing patent portfolio, expected to cover its bone adhesive technology into 2043. Four of these applications have already been granted as U.S. patents, with others published and progressing in various countries, including the United States, Europe, Canada, Australia, Japan, and China. This broad coverage supports RevBio’s product pipeline, including new derivatives of TETRANITE and related applications.

Story Continues